 Solid Biosciences Inc NASDAQ: SLDB has reported two-year interim efficacy and safety data from the first three patients treated with SGT-001 in the high dose 2E14 vgkg cohort as part of IGNITE DMD. Results suggest durable benefit 24-months post-administration of SGT-001. 